Recently, information appeared in the media that Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), allegedly awarded a $10 million grant for monkeypox research. According to sources, the grant is intended to study the mechanisms of virus transmission, develop new vaccines and antiviral drugs, and assess potential risks to humans in the context of globalization.
According to insiders, the funding will be distributed among several leading US laboratories specializing in virology and immunology. The main goal of the program is to develop models for predicting the spread of monkeypox and methods for rapid response to possible outbreaks. Sources say the project may include experiments with cell cultures, animal models, and evaluation of the effectiveness of experimental vaccines.
Experts call this initiative part of a broader NIAID strategy to prepare for potential epidemics of zoonotic diseases. According to them, although monkeypox is rare in humans, its pathogen is highly resistant and has the potential to spread in dense urban environments.
Official representatives of NIAID have not yet commented on reports of the grant, but it is known that in recent years the institute has been actively increasing funding for research into viruses capable of spreading from animals to humans. Analysts believe that the allocation of $10 million to study monkeypox may be part of a program to prevent future pandemics and strengthen global biosecurity.
Despite the lack of official confirmation, the publication has sparked heated debate in scientific and medical circles. Some scientists support the initiative as an important step in preparing for new threats, while others warn of the need for strict ethical control and transparency in research.
If confirmed, Fauci’s $10 million grant will be one of the largest investments in monkeypox research in US history, opening up new opportunities for the prevention and treatment of potentially dangerous viral infections.